eGenesis raises $38M series A

Xenotransplantation play eGenesis Inc. (Boston, Mass.) raised the first tranche of a $38 million series A round co-led by Biomatics Capital Partners and Arch Venture Partners. Khosla Ventures, Alta Partners, Alexandria Real Estate Equities, Heritage Provider Network, Berggruen Holdings North America Ltd., Uprising and Fan Ventures also participated. Details regarding the round's tranches are undisclosed.

Using a CRISPR-based approach, eGenesis seeks to eliminate porcine endogenous retroviruses (PERVs) and genes involved in immunogenicity from pig donor tissue to enhance the safety of xenotransplants (see BioCentury Innovations, Oct. 22, 2015). ...